Forest Namenda Has 10% Off-Label Use Based On Initial Launch Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The company said 70% of use was in moderate Alzehimer's cases and 20% was in severe cases. The company expects to file an sNDA for a mild-to-moderate indication by "late this summer."
You may also be interested in...
Forest To Test Alzheimer’s Drug Neramexane As Monotherapy in Phase II/III Trial
The NMDA receptor agonist failed to show efficacy as a combination therapy with acetylcholinesterase inhibitors in pivotal trial for moderate-to-severe disease, Forest says.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.